Efficacy of venlafaxine extended-release monotherapy for first-episode depression with painful physical symptoms

NeuroReport

Volumn 24, Issue 7, 2013, Pages 364-369

  Huang, Xiao ^a   Li, Chao ^b   Luo, Yan Li ^c   Wang, Biao ^b   Ji, Jian Lin ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VENLAFAXINE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAM; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; REMISSION; SHOULDER PAIN; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; VITAL SIGN; WITHDRAWAL SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COHORT STUDIES; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84876406930     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0b013e3283601a3e     Document Type: Article

References (47)

1. Kroenke K. The interface between physcial and psychological symptoms. Prim Care Companion J Clin Psychiatry 2003; 5 (Suppl 7):11-18.
2. Sternbach RA. Survey of pain in the United States: the Nuprin Pain Report. Clin J Pain 1986; 2:49-53. (Pubitemid 17188450)
3. Verhaak PF, Ferssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998; 77:231-239. (Pubitemid 28451511)
4. Schappert SM. National Ambulatory Medical Care Survey: 1989 summary. National Center for Health Statistics. Vital Health Stat 1992; 13:1-80.
5. Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998; 279:1548-1553. (Pubitemid 28233010)
6. Smith BH, Elliott AM, Chambers WA, Smith WC, Hannaford PC, Penny K. The impact of chronic pain in the community. Fam Pract 2001; 18:292-299. (Pubitemid 32514684)
7. Bair MJ, Richardson KM, Dobscha SK, Yi EJ, Gerrity MS, Kroenke K. Chronic pain management guidelines: a systematic review of content and strength of evidence (Abstract). J Gen Intern Med 2005; 20 (Suppl 1):62.
8. Chodosh J, Ferrell BA, Shekelle PG,Wenger NS. Quality indicators for pain management in vulnerable elders. Ann Intern Med 2001; 135:731-735. (Pubitemid 33015486)
9. Stahl SM. The psychopharmacology of painful physical symptoms in depression. J Clin Psychiatry 2002; 63:382-383. (Pubitemid 34507213)
10. Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry 2003; 64 (Suppl 13):26-29. (Pubitemid 37267812)
11. Delgado PL. Common pathways of depression and pain. J Clin Psychiatry 2004; 65 (Suppl 12):16-19.
12. Barkin R, Fawcett J. The management challenges of chronic pain: the role of antidepressants. Am J Ther 2000; 7:37-47.
13. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry 2000; 7:257-277. (Pubitemid 30051667)
14. Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 1996; 8:459-476. (Pubitemid 26163141)
15. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48:980-990.
16. Arnold LM, Lu Y, Crofford LJ,Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50:2974-2984. (Pubitemid 39209537)
17. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119:5-15. (Pubitemid 41752960)
18. Arnold LM, Prichett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 2007; 16:1145-1156. (Pubitemid 47587341)
19. Paykel ES. Use of the Hamilton Depression Scale in general practice. In: Bech P, Coppen A, editors. The Hamilton scales. Berlin: Springer-Verlag; 1990. pp. 40-47.
20. Huskisson EC. Measurement of pain. J Rheumatol 1982; 9:768-769.
21. Chapman CR, Case KL, Dubner R, Foley KM, Gracely RH, Reading AE. Pain measurement: an overview. Pain 1985; 22:1-31. (Pubitemid 15037578)
22. Sherbourne CD. Measuring health: a guide to rating scales and questionnaires. 2nd ed. New York: Oxford University Press Inc.; 1996. pp. 357-358.
23. Luo YL, Zhang MY, Wu WY, Li CB. Reliability and validity of Medical Outcomes Study Pain Measurement (MOSPM) in patients with back pain. Chin Mental Health J 2006; 20:713-715.
24. Ang DC, Kroenke K, McHorney CA. Impact of pain severity and location on health-related quality of life. Rheumatol Int 2006; 26:567-572.
25. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003; 163:2433-2445. (Pubitemid 37385786)
26. Magni G, Marchetti M, Moreschi C, Merskey H, Luchini SR. Chronic musculoskeletal pain and depressive symptoms in the National Health and Nutrition Examination, I: epidemiologic follow-up study. Pain 1993; 53: 163-168. (Pubitemid 23161578)
27. Thomas MR,Waxmonsky JA, Gabow PA, Flanders-McGinnis G, Socherman R, Rost K. Prevalence of psychiatric disorders and costs of care among adult enrollees in a Medicaid HMO. Psychiatr Serv 2005; 56:1394-1401. (Pubitemid 41579774)
28. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 1997; 13:116-137. (Pubitemid 27251106)
29. Arnow BA, Hunkeler EM, Blasey CM, Lee J, Constantino MJ, Fireman B, et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 2006; 68:262-268. (Pubitemid 43740130)
30. Demyttenaere K, Bonnewyn A, Bruffaerts R, Brugha T, De Graaf R, Alonso J. Comorbid painful physical symptoms and depression: prevalence, work loss, and help seeking. J Affect Disorder 2006; 92:185-193.
31. Kroenke K. The interface between 'physical' and psychological symptoms. Prim Care Companion J Clin Psychiatry 2003; 5:11-18.
32. Von Korff M, Simon G. The relationship between pain and depression. Br J Psychiatry Suppl 1996; 30:101-108. (Pubitemid 26179810)
33. Ronald HB, Robert LB, John J, DeYoung K, Dodge CW. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003; 10:318-323.
34. Taylor K, Rowbotham MC. Venlafaxine hydrochloride and chronic pain. West J Med 1996; 165:147-148.
35. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005; 3:CD005454.
36. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96:399-409. (Pubitemid 40835693)
37. Songer DA, Schulte H. Venlafaxine for the treatment of chronic pain. Am J Psychiatry 1996; 153:737.
38. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003; 37:1561-1565. (Pubitemid 37315091)
39. Karp JF. Venlafaxine XR and chronic pelvic pain syndrome. J Clin Psychiatry 2004; 65:880-881.
40. Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98 (Pt 1):737-744. (Pubitemid 33042538)
41. Reuben SS. The prevention of post-surgical neuralgia. Pain 2005; 113:242-243.
42. Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45:144-152. (Pubitemid 40315784)
43. Zissis NP, Harmoussi S, Vlaikidis N, Mitsikostas D, Thomaidis T, Georgiadis G, Karageorgiou K. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 2007; 27:315-324. (Pubitemid 46434967)
44. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Søgaard J. Efficacy and tolerability of venlafaxine in geriatric patients with major depression: a double-blind, randomised 6 month comparative trial with citalopram. Int J Geriatr Psychiatry 2004; 9:1123-1130. (Pubitemid 40028341)
45. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 2006; 14:361-370.
46. Cervera-Enguix S, Baca-Baldomero E, Garcia-Calvo C, Prieto-López R. TESEO Study Group. Depression in primary care: effectiveness of venlafaxine extended-release in elderly patients. Observational study. Arch Gerontol Geriatr 2004; 38:271-280. (Pubitemid 38456869)
47. Juan J, Jose L, Rita P, García-Calvo C; Ceres Study Group. Effective and safety of venlafaxine extended release in elderly depressed patients. Arch Gerontol Geriatr 2008; 46:317-326. (Pubitemid 351454046)